Interpretation of breast cancer pathology report

What’s the letter on the breast cancer pathology report? What does it mean to be endocrine? Even the doctors are here today to teach you how to read pathology reports and understand your own analysis. First of all, we need to focus on the data from the pathology report on ERP. ER is for estrogen receptor, and PR is for sterogen receptor. Both hormones are closely related to the occurrence of breast cancer. Any one of them is greater than or equal to 1 per cent, which means you’re hormonal positive and sensitive to endocrine treatment. This category is indeed the most common, with relatively slow overall tumour development and better cure and survival rates. Early detection can even take place without chemotherapy, and endocrinology can do the cure. The second indicator of concern is the Her2 indicator, and three additional numbers after Her2 are determined to be Her2 positive. If there are two additional signs that mean uncertainty, further tests of the ruins are needed to determine whether Her2 is positive or negative. The overall tumour of Her2 positive will then grow faster and more easily shift than the hormonal receptors mentioned earlier. However, there is a very high number of tumour treatment-oriented drugs available for use, and there is no need to be overly anxious. And finally, it’s called triple-negative breast cancer. From the pathology report, ER, the PR is followed by a small bar, which means it’s negative. So Her2 is a plus or zero patient and can also be considered to be spat. And of course, Her 2 plus. However, patients who had to be examined were negative, and ERPR, HER2, were both negative, which was described as triple-negative breast cancer. The cancer cells of these tumours are developing most rapidly, with the highest rates of relapse and transfer, and are easily transferred to the internal organs. For example, the lungs and the brain are all parts of it that can easily be moved. Usually, patients in the hospital have the highest risk of relapses between one and five years after the surgery. However, the chances of relapses after five years are lower than those mentioned earlier for endocrine-positive persons and those who are excretant. The treatment currently available is more limited, as patients with triple-negative breast cancer have no corresponding target. Clinical treatment is mainly based on chemotherapy, and there are still a lot of high-quality drugs under development, with some confidence and hope in the treatment of triple-negative breast cancer.